AKT-IN-24
KT-IN-24 (Compound M17) is a AKT allosteric inhibitor with anti-tumor activity. KT-IN-24 can target the AKT/mTOR and MEK/ERK signaling pathways and inhibit epithelial-mesenchymal transition, which has a synergistic suppressive effect on TNBC, promoting cell apoptosis while inhibiting proliferation and migration when used in combination with Trametinib.
Product Specifications
UNSPSC
12352005
Target
Akt; Apoptosis; ERK; MEK; mTOR
Related Pathways
Apoptosis; MAPK/ERK Pathway; PI3K/Akt/mTOR; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Smiles
O=[N+](C1=C(C=CC=C1)OCC(NC2=CC=CC(CC(O[C@H](C/C=C(C)\C)C3=CC(C4=C(O)C=CC(O)=C4C3=O)=O)=O)=C2)=O)[O-]
Molecular Formula
C32H28N2O10
Molecular Weight
600.57
References & Citations
[1]Hongwei Han, et al. Trametinib and M17, a novel small molecule inhibitor of AKT, display a synergistic antitumor effect in triple negative breast cancer cells through the AKT/mTOR and MEK/ERK pathways. Bioorg Chem. 2024 Nov 22:154:107981.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
RAF-001-2 2 mL
TRITC Conjugated Goat Affinity Purified Antibody to Human IgG
Sign In for Pricing
View Details 
BNC942281-500 1x 500 µL
HLA-DRB (MHC II) (DA2), CF594 conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
